Cost-effectiveness analysis of treatment of atherosclerotic cardiovascular disease with hybutimibe
ZHANG Xiao-han
JU Wen-xiang
ZHAO Ying-ying
SHEN Ai-zong
Abstract：Objective:To evaluate the cost-effectiveness of hybutimibe combined with atorvastatin and atorvastatin monotherapy in treatment of the hypercholesterolaemia patients with atherosclerotic cardiovascular disease.Methods:A Markov model was established based on the report of the phase Ⅲ clinical trial of hybutimibe and the published literature,with a study timeframe 30 years,and the economical efficiency of the hybutimibe combined with atorvastatin group was evaluated by the incremental cost-effectiveness ratio(ICER),and the reliability of the results was verified by means of univariate sensitivity analysis and probabilistic sensitivity analysis.Results:Compared with the atorvastatin monotherapy group,the 30-year health output of the hybutimibe combined with atorvastatin group was increased by 0.37 quality-adjusted life-years(QALYs)while the cost was increased by 28269 yuan,with an ICER of 76756 yuan/QALY,lower than our per capita GDP,and it is an economically viable option,and the resulted were verified by the sensitivity analyses.Conclusion:Compared with the atorvastatin monotherapy group,the regimen of hybutimibe in combination with atorvastatin has more advantages in cost-effectiveness for the treatment of the hypercholesterolaemia patients with atherosclerotic cardiovascular diseases.
Keywords：HybutimibeAtherosclerotic cardiovascular diseaseCost-effectiveness analysisMarkov model
Publication Date：2023-08-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 287-290 )